Keros Therapeutics, Inc. (KROS)
Pharmaceutical Preparations
Latest Price
$11.17
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
13.31
P/B Ratio
0.84
Valuation metrics
adjust assumptions →EPS: $2.30
Book value / share: $15.51
Formula: √(22.5 × EPS × BVPS)
Graham Number
$28.33
+154% upside
EPS: $2.30
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$34.50
+209% upside
Institutional Ownership
93.2% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2.79M | $29.0M | 14.09% | +382.4K | 2026-06-30 |
| Nantahala Capital Management, LLC | 1.41M | $15.0M | 7.11% | +50.0K | 2026-06-30 |
| AQR CAPITAL MANAGEMENT LLC | 967.9K | $10.0M | 4.88% | +561.3K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 833.6K | $8.0M | 4.20% | +2.2K | 2026-06-30 |
| ORBIMED ADVISORS LLC | 759.2K | $8.0M | 3.83% | -- | 2026-06-30 |
| FEDERATED HERMES, INC. | 700.4K | $7.0M | 3.53% | +11.2K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 652.6K | $6.0M | 3.29% | -29.4K | 2026-06-30 |
| MACKENZIE FINANCIAL CORP | 628.4K | $6.0M | 3.17% | +476.0K | 2026-06-30 |
| Madison Avenue Partners, LP | 626.6K | $6.0M | 3.16% | -- | 2026-06-30 |
| Qube Research & Technologies Ltd | 608.8K | $6.0M | 3.07% | -116.1K | 2026-06-30 |